Abstract
Introduction
Small-cell lung cancer (SCLC) accounts for up to 16% of lung cancer cases [1] . The main treatment is chemotherapy, and cisplatin plus etoposide is the standard regimen [2, 3] . Concurrent thoracic radiotherapy (TRT) improves overall survival (OS) if all lesions can be included in one radiotherapy field ("limited disease" -LD SCLC) [4] .
Prophylactic cranial irradiation (PCI) reduces the risk of brain metastases and prolongs survival in those who respond to chemo-radiotherapy [5] . Up to 90% of patients respond to the treatment, but most relapse and die from this disease [2, 6] .
Several schedules of TRT are being used in LD SCLC, but few comparative trials have been conducted. The most known study, by Turrisi et al., compared twicedaily TRT (45 Gy/30 fractions, 3 weeks) with once-daily TRT (45 Gy/25 fractions, 5 weeks). Response rates were equal (87%), but twice-daily TRT significantly prolonged median OS (23.0 months vs. 19 .0 months; p=0.04) [6] . Thus, twice-daily TRT is the most recommended schedule, but not universally adopted [7] [8] [9] [10] [11] . Inconvenience of this schedule and concerns about esophagitis are probably the main explanations [10] .
Furthermore, the different duration of the schedules (3 vs. 5 weeks) and dissimilar biologically effective doses might have contributed to the OS-difference [6] ; a systematic overview concluded that shortening the treatment time from start of chemotherapy until completion of TRT was associated with a prolonged OS [12] .
A three-week schedule of once-daily hypofractionated TRT (40 Gy in 15 fractions) was one of the schedules included in the meta-analysis establishing TRT in LD SCLC [4] . Similar schedules have been used in Norway and other countries [2, 9, 11, 13] , but have never been compared with twice-daily TRT in a randomized trial. The aims of this study were to compare 45 Gy/30 fractions (twice daily -BID) with 42
Phase II trial comparing once and twice daily TRT in LD SCLC 5 Gy/15 fractions (once daily -OD) TRT in LD SCLC with respect to progression free survival (PFS), overall survival (OS), toxicity and health related quality of life (HRQoL). The hypothesis was that BID-regimen would be feasible and improve efficacy without severely increase toxicity.
Material and Methods

Design and approvals
This randomized phase II trial was approved by the Regional Committee for Medical Research Ethics, Central Norway; the Norwegian Social Science Data Services; and the Norwegian Directorate for Health and Social Affairs.
Eligibility criteria and random assignment
A CT of the chest/upper abdomen, brain MRI and bone scan were conducted within three weeks prior to inclusion. Eligible patients gave written informed consent; were ≥ 18 years old (no upper limit); had SCLC ineligible for surgery and confined to one hemithorax and the mediastinum, contralateral hilus and supraclavicular regions; measurable disease according to RECIST v1.0 [14] ; no other active cancer; no prior chest-radiotherapy; WHO performance status (PS) 0-2; leukocytes ≥3.0 x 10 9 /l, platelets ≥100 x10 9 /l, bilirubin <1.5 x ULN and creatinine <125 mol/l. One negative cytology was required if pleural effusion was present.
Patients were randomized to receive TRT of 42 Gy/15 fractions (OD) or 45
Gy/30 fractions (BID) in blocks of eight and stratified for the five Norwegian health care regions.
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Chemotherapy
Patients were to receive four courses of cisplatin 75 mg/m 2 IV day 1 and etoposide 100 mg/m 2 IV days 1-3 every 3 weeks (PE). A full dose was administered if leukocytes were ≥3.0 x 10 9 /l and platelets ≥100 x 10 9 /l on day 22. Doses were reduced by 25% if leukocytes were 2.5-2.99 x 10 9 /l or platelets 75-99 x 10 9 /l on day 22. At lower leukocyte-or platelet counts, courses were postponed. Dose-reductions were maintained for subsequent cycles. Use of G-CSF was not recommended. Chemotherapy was discontinued if a course was delayed more than three weeks or a third dose-reduction was warranted. Carboplatin was allowed if cisplatin was not tolerated. The use of other agents was not addressed in the protocol.
Radiotherapy
All patients received 3D conformal TRT five days a week starting between three and Phase II trial comparing once and twice daily TRT in LD SCLC 7
Other normal tissue constraints were defined and treatment verification was done according to local routines.
A CT response evaluation was conducted three weeks after the last PE-course.
Patients with a complete or near complete response were offered prophylactic cranial irradiation (PCI) of 30 Gy/15 fractions starting within six weeks after the CT evaluation.
Endpoints
Primary endpoint was 1-year PFS. Secondary endpoints were OS, toxicity and
HRQoL (global quality of life, dysphagia and dyspnea).
Evaluation and follow up
All patients were clinically examined and assessed for toxicity before each PE-course and weekly during TRT. Response evaluation was performed three weeks after the last PE. Confirmation of response was not required. Post-therapy, patients were followed every eight weeks year 1, every four months year 2-3, and every six months year 4-5. A
CT of the chest/upper abdomen was done at each evaluation year 1. Later, a chest x-ray or CT scan (optional) was performed. Progressive disease (PD) was to be confirmed with a CT scan. 
Statistical considerations
To detect a 30% improvement in 1 year PFS (from 70% to 91%) from BID TRT with a two-sided alpha of 0.05 and a beta of 0.20, 75 patients were required in each arm. We expected a loss to follow-up of <10% and aimed at enrolling 83 patients in each arm.
Patients who received at least one PE-course and one fraction of TRT were included in the analyses.
HRQoL-scores were calculated according to the QLQ-C30 scoring-manual . The clinically relevant minimum difference in mean scores was defined as 10 (on a scale from 0 to 100) [15] .
Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Pearson's Chi-square and Fisher's exact tests were used for group comparisons. The Cox proportional hazard method was used for multivariate analyses.
The level of significance was defined as p<.05.
Results
Patients
patients were enrolled between May 2005 and January 2011 at 18 hospitals in
Norway. Fourteen patients were excluded: extensive disease (n=9), withdrawn consent (n=2), carcinoid tumour (n= 2), and prior chest radiotherapy (n=1). Thus, 157 were analysed (OD: 84 patients, BID: 73) (Figure 1 ). The imbalance in number of patients in each arm was partly due to the block randomization.
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Median age was 63 years, 26% were ≥70 years, 52% were men, 84% had PS 0-1, 72% had stage III disease and 11% had cytologically negative pleural fluid. Baseline characteristics were balanced between the arms (Table 1) .
Median follow-up for PFS was 59 months (range: 29-97); 34 patients were progression free when the analyses were performed (July, 2013). Median follow-up for OS was 81 months (range: 52-119); 34 patients were alive at the time of the analyses (April, 2015).
Study therapy
More OD-patients completed chemotherapy without delays (OD: 42%, BID: 26%;
p=.04). There were no other differences in chemotherapy. Fourteen patients received other chemotherapy due to cisplatin toxicity (OD: n=10, BID: n=4) ( Table 2 ).
The completion rate of TRT was similar (OD: 96%, BID: 97%). Mean doses were OD: 41.8 Gy (range: 34-45) and BID: 44.7 Gy (range: 30-46). 82% of OD patients and 84% of BID patients received PCI. PCI was omitted in 27 patients due to poor response (n=21), poor PS (n=3), patients' decision (n=3) and death (n=1) ( Table 2) . (Figure 2 ). The difference in median diseasespecific survival was of similar magnitude (OD: 20.9 months, BID: 29.5 months;
Response to therapy, PFS and OS
p=.56).
Toxicity
There were no differences in grade 3-4 neutropenic infections (OD: 44%, BID: 37%; p=.37), grade 3-4 esophagitis (OD: 31%, BID: 33%; p=.80) or grade 3-4 pneumonitis (OD: 2%, BID: 3%; p=1.0) ( Table 3 ). There was no difference in treatment-related deaths (OD: n=4, BID: n=3; p=1.0). Four patients died from radiation pneumonitis (OD: n=3, BID: n=1). Three patients died within 30 days of chemoradiotherapy: hemoptysis (n=1), coronary disease (n=1) and respiratory failure (n=1).
HRQoL
The completion rate of the questionnaires was 85-97% of patients alive at each time point and similar in both arms. Patients in the BID-arm experienced more dysphagia at the end of TRT (mean score OD: 61, BID: 72) (Figure 3 ). There were no other differences in global QoL, dysphagia, dyspnea or in any other HRQoL-domain.
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Post-study treatment
Seventy-five patients received second line chemotherapy (OD: 51%, BID: 44%; p=.36) ( Table 2) . Re-induction with etoposide plus cisplatin or carboplatin was the most common regimen (37/75 patients; 49%).
PS and stage of disease
All patients were analyzed as one cohort in these explorative analyses. 
Discussion
In this RCT comparing two 3-week schedules, the twice-daily TRT-schedule provided significantly more complete responses, but not higher response-rates. There were no Phase II trial comparing once and twice daily TRT in LD SCLC 12 statistically significant differences in PFS or OS, though the median OS (25.1 vs. 18.8 months) and disease-specific survival (29.5 vs. 20.9 months) were more than 6 months longer on the BID-arm. The BID-patients reported slightly more dysphagia immediately after radiotherapy, but a difference in mean score of 10 to 20 is considered a "moderate change" [15] ; they had slightly more dysphagia also before radiotherapy; and patients on both arms regained similar, pre-treatment levels of dysphagia soon after therapy. Thus, there were no differences in severe toxicity or treatment related deaths. We used a wide definition of limited disease, had no restrictions regarding comorbidity or age and 16% of the patients had PS 2.
Approximately 17% of all patients diagnosed with LD SCLC in Norway during the enrolment period participated in the trial.
We are aware of two other prospective RCTs comparing one and two daily fractions of TRT in LD-SCLC. The split course used by Schild et al. [16] causes longer treatment duration and might enhance repopulation of cancer cells [12] . Thus, it is most relevant to compare our results with the study by Turrisi et al. In this study,
TRT of 45 Gy in 30 fractions (BID) was compared with 45 Gy in 25 fractions (OD).
All patients received cisplatin plus etoposide. Patients on the BID arm had significantly longer median OS (23.0 vs. 19.0 months; p=.04) [6] . The survival difference is of similar magnitude in our smaller study, though not statistically significant. Furthermore, the difference in median OS in our study did not result in a higher proportion of long-term survivors.
Results from other studies might indicate that twice-daily regimens are superior to hypo-fractionated 3-week schedules. In two studies, patients on the control arms receiving four courses of cisplatin plus etoposide and TRT of 45 Gy/30 fractions Phase II trial comparing once and twice daily TRT in LD SCLC 13 achieved response rates of 95-97%, median PFS of approximately 13 months, and median OS of 25-38 months [17, 18] . In studies administering TRT with 40-42 Gy/15 fractions, response rates were 81-85%, median PFS 10.6 months and median OS 13.7-21.2 months [2, 11, 13] . However, these studies are not necessarily comparable due to differences in patient selection, staging procedures, chemotherapy, timing and schedules of TRT, response-evaluation and follow-up.
Turrisi et al. reported more esophagitis grade 3 (27% vs. 11%) but not more grade 4 (5% both arms) in the BID group. We found a similar proportion of grade 3-4 esophagitis in the BID arm (33%), but a higher proportion in our OD arm (31%) -probably due to the higher daily dose. The percentage of deaths from radiation pneumonitis (4%) in the OD-arm is higher than in other reports [6, 13] , but the number was low (n=3).
PFS was chosen as the primary endpoint since it correlates well with OS in several studies of SCLC and is less influenced by relapse treatment and death of other causes [6, 19] . However, using PFS as the primary endpoint can be debated.
Distinguishing between relapse and radiation fibrosis in lung tissue is challenging, there was a large number of radiologists involved in this study, and no central review of CT images. On the other hand, assessment of progression was done equally in both arms.
The assumptions for our sample size calculation were incorrect. The delta value in the calculation was rather large, but we considered the sample size adequate to guide directions for future research. Other reasons for limiting the sample size were concerns about toxicity of the BID-schedule, as well as concerns about inferiority of the ODschedule.
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A limitation of the study is the lack of PET/CT for staging of disease. PET/CT identifies pathological lesions better than CT-and bone-scans [20] , allowing for more accurate staging and definition of radiotherapy fields for TRT [21] . However, PET/CT was not generally available in Norway at the time when this study was conducted. The use of elective nodal irradiation could have been avoided if PET/CT was used for staging.
Further, there may have been some technical development in radiotherapy during the six year inclusion period. The annual number of patients per hospital was low, and we had no central quality assurance of radiotherapy. We have no information on patients not included into the trial. It is difficult to draw any firm conclusions about efficacy from this phase II trial. The higher rate of complete responses and the longer median overall survival may indicate superiority of the BID-schedule. But no corresponding difference in PFS was observed, and there was a trend towards more local relapses at first recurrence in the BID-arm. Besides, the difference in median overall survival was not statistically significant, and there were no differences in 4-year survival rates. Thus, a phase III study is needed before one can conclude whether the BID-schedule is more effective than the OD-schedule. Considering the results of the present study, the hypothesis of such a trial should be that BID is superior to OD.
A large number of patients would be required, and by conducting such a study, many patients might receive an inferior treatment -which would probably be equally toxic as the BID-schedule. Thus, we assume that the relevance of such a trial is limited.
By using PET/CT for target volume definition and advanced radiotherapy techniques, higher TRT doses can be delivered and there are indications that 60-70 Gy in 6-7 weeks may be superior to 45 Gy/30 fractions [22] [23] [24] . In line with this, we have Despite improvements in radiotherapy-techniques it may not be possible to deliver 60-70 Gy to all patients with disseminated intra-thoracic disease, severe comorbidity or poor PS. Thus, some patients might receive TRT doses of 40-45 Gy also in the future. Our study indicates that concerns about toxicity should not be a reason for choosing hypo-fractionated instead of twice-daily TRT.
In conclusion, there was no difference in toxicity between the two TRTschedules. The twice-daily schedule was feasible and resulted in more complete responses and a numerically longer median overall survival. There was no difference in progression free survival, and the survival-difference was not statistically significant.
Thus, no firm conclusions about efficacy could be drawn from this phase II trial.
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